Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 15/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073475 | 1.00 | REN (0.52) | RENCYP3A4ADRB3LMNAMAPT | |
| SCHEMBL4975236 | 0.88 | REN (0.51) | RENCYP3A4ADRB3 | |
| SCHEMBL4968733 | 0.88 | REN (0.56) | RENCYP3A4 | |
| SCHEMBL4968724 | 0.88 | REN (0.56) | RENCYP3A4 | |
| SCHEMBL971028 | 0.88 | REN (0.51) | RENCYP3A4ADRB3LMNAMAPT | |
| SCHEMBL971027 | 0.88 | REN (0.51) | RENCYP3A4ADRB3LMNAMAPT | |
| SCHEMBL969066 | 0.87 | REN (0.49) | RENCYP3A4ADRB3LMNAMAPT | |
| SCHEMBL3611251 | 0.87 | REN (0.49) | RENCYP3A4ADRB3LMNAMAPT | |
| SCHEMBL969063 | 0.87 | REN (0.49) | RENCYP3A4ADRB3LMNAMAPT | |
| SCHEMBL9914198 | 0.87 | REN (0.49) | RENCYP3A4ADRB3LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |